Sugi Predict

Sugi Predict / Compounds / SCHEMBL26933366

SCHEMBL26933366

SCHEMBL26933366

CCOC(=O)CC(C(=O)OC)c1cc(F)cc2ccncc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 5/20 0.37
▸ HPGD P15428 2/20 0.37
▸ CASP1 P29466 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ CASP7 P55210 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ BRAF P15056 1/20 0.35
▸ EIF2AK3 Q9NZJ5 1/20 0.35
▸ TSHR P16473 1/20 0.34
▸ KDM5A P29375 1/20 0.34
▸ KDM5B Q9UGL1 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ MAOA P21397 2/20 0.33
▸ GPBAR1 Q8TDU6 1/20 0.33
▸ CDC7 O00311 1/20 0.33
▸ DBF4 Q9UBU7 1/20 0.33
▸ NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29890084 0.86 ALDH1A1 (0.36) ROCK2HPGDCASP1ALDH1A1KDM4E
SCHEMBL26933109 0.86 ALDH1A1 (0.36) ROCK2HPGDCASP1ALDH1A1KDM4E
SCHEMBL26933407 0.80 MAOA (0.39) ROCK2ALDH1A1KDM4EGAAMAOA
SCHEMBL26933567 0.70 MAOA (0.42) HPGDALDH1A1KDM4EGAAMAOA
SCHEMBL29137949 0.69 KDM4E (0.40) ROCK2ALDH1A1KDM4EGAAMAOA
SCHEMBL18524318 0.69 CDK9 (0.40) MAOAGPBAR1NAMPT
SCHEMBL30636318 0.69 MAOA (0.38) KDM4EMAOA
SCHEMBL26933604 0.69 MAOA (0.38) KDM4EMAOA
SCHEMBL4672007 0.68 LTA4H (0.42) NAMPT
SCHEMBL16092088 0.68 CDC25B (0.43) HPGDALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof BAUSCH + LOMB IRELAND LIMITED (IE) 2025-10-07 — — US disclosed
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2024-09-19 — — US disclosed
EP-4313951-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-02-07 — — EP disclosed
US-11845730-B2 1,3-substituted cyclobutyl derivatives and uses thereof CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2023-12-19 — — US disclosed
CN-117062804-A 1, 3-substituted cyclobutyl derivatives and their use 诺华股份有限公司 2023-11-14 — — CN disclosed
US-20220324811-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2022-10-13 — — US disclosed
WO-2022201097-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2022-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845730-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 ROCK2 3766/4885HPGD 570/4885CASP1 1205/4885
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 ROCK2 3766/4885HPGD 570/4885CASP1 1205/4885
US-20220324811-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF TRPV1, TRPV3, TRPV2 ROCK2 3766/4885HPGD 570/4885CASP1 1205/4885
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF TRPV1, TRPV3, TRPV2 ROCK2 3766/4885HPGD 570/4885CASP1 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.